Effects of Cisatracurium on Succinylcholine-induced Fasciculations and Myalgia
NCT02481193 · Status: COMPLETED · Phase: PHASE3 · Type: INTERVENTIONAL · Enrollment: 90
Last updated 2015-06-25
Summary
The purpose of this study is to investigate the effects of different doses of cisatracurium pretreatment on succinylcholine-induced fasciculations and postoperative myalgia.
Conditions
- Fasciculation
Interventions
- DRUG
-
Cisatracurium
Different doses of cisatracurium pretreatment
Sponsors & Collaborators
-
Yangzhou No.1 People's Hospital
lead OTHER
Study Design
- Allocation
- RANDOMIZED
- Purpose
- PREVENTION
- Masking
- QUADRUPLE
- Model
- PARALLEL
Eligibility
- Min Age
- 20 Years
- Max Age
- 65 Years
- Sex
- ALL
- Healthy Volunteers
- Yes
Timeline & Regulatory
- Start
- 2013-03-31
- Primary Completion
- 2014-01-31
- Completion
- 2014-01-31
More Related Trials
-
Effect of Addition of Cisatracurium to Lidocaine VS Plain Lidocaine
NCT06214169 ·Status: COMPLETED ·Phase: NA
-
Efficacy of Caudal Block on Intra-operative Anal Sphincter Muscle Tone and Post-operative Analgesia During Anal Sphincter Sparing Procedures Under General Anaesthesia
NCT04651595 ·Status: COMPLETED ·Phase: NA
-
Influence of Neuromuscular Block on Mask Ventilation
NCT01849211 ·Status: COMPLETED ·Phase: NA
-
Effect of Prilocaine on Motor Block During Caesarean Section
NCT06133881 ·Status: COMPLETED ·Phase: PHASE4
-
Ketamine or Neostigmine for Serratus Anterior Plane Block in Modified Radical Mastectomy
NCT04544228 ·Status: COMPLETED ·Phase: NA
-
Pilot Study: Rectus Sheath Blocks for Improving Abdominal Surgery Conditions
NCT02447965 ·Status: TERMINATED ·Phase: NA
-
Effect of Paravertebral Muscle Fat Infiltration on Rocuronium Use in Lumbar Surgery
NCT05619848 ·Status: COMPLETED ·Phase: EARLY_PHASE1
-
Effect of Adding Midazolam Versus Fentanyl to Intrathecal Levobupivacaine in Patients Undergoing Caesarean Section
NCT03824314 ·Status: COMPLETED ·Phase: PHASE1
-
Observational Study to Evaluate the Current Neuromuscular Monitoring Practice Used After Different Types of Surgery, for Which Neuromuscular Blocking Agents Were Used, With or Without Blocking Reversal (P06556)
NCT01213264 ·Status: COMPLETED
-
Pharmacokinetics and Pharmacodynamics of Sugammadex in Reversal of Vecuronium-induced Neuromuscular Blockade
NCT04131218 ·Status: UNKNOWN ·Phase: PHASE4
-
Abdominoplasty Under Spinal Anesthesia
NCT03810547 ·Status: COMPLETED ·Phase: NA
-
Local Anesthetic Injection Into Both Angles of the Rectus Sheath Incision
NCT02285491 ·Status: COMPLETED ·Phase: EARLY_PHASE1
-
Comparison Between Pregabalin and Magnesium Sulfate in Hypotensive Anaesthesia
NCT05442931 ·Status: UNKNOWN ·Phase: PHASE1/PHASE2
-
Rocuronium and Supramaximal Stimulation
NCT05294523 ·Status: UNKNOWN ·Phase: NA
-
Quality of Recovery After Reversal With Neostigmine or Sugammadex.
NCT02909439 ·Status: COMPLETED ·Phase: PHASE4
-
The Effect of Sugammadex During Transcranial Electrical Motor Evoked Potential Monitoring in Spinal Surgery
NCT04471376 ·Status: COMPLETED ·Phase: NA
-
Combined Use of Low-dose Sugammadex Plus Neostigmine Administered for Reversal of Rocuronium
NCT03328312 ·Status: UNKNOWN ·Phase: EARLY_PHASE1
-
Dexmedetomidine in Obturator Nerve Block as an Analgesic in Transurethral Surgeries
NCT06229054 ·Status: COMPLETED ·Phase: EARLY_PHASE1
-
Influence of Muscle Relaxation on a Closed-loop Anesthesia System
NCT00886418 ·Status: COMPLETED ·Phase: PHASE3
-
Impact of Deep Versus Standard Muscle Relaxation on Intra-operative Safety
NCT04124757 ·Status: COMPLETED ·Phase: NA
-
Dose Finding Study for Effective Reversal of a Deep Rocuronium-induced Neuromuscular Block With Sugammadex in Morbidly Obese Patients
NCT01911520 ·Status: COMPLETED ·Phase: PHASE2
-
Minimum Effective Dose of Ropivacaine for Spinal Anesthesia for Cesarean Delivery
NCT02565303 ·Status: COMPLETED ·Phase: NA
-
Efficacy, Safety and Pharmacokinetics of Sugammadex (Org 25969; MK-8616) at 3 Different Time Points After 0.6 mg/kg Esmeron® in Male Participants (P05940; MK-8616-020).
NCT03519854 ·Status: COMPLETED ·Phase: PHASE2
-
Use of Sugammadex Administered at 5 Minutes After Administration of 1.2 mg/kg Esmeron® (19.4.205)(P05942)
NCT00379613 ·Status: COMPLETED ·Phase: PHASE2
-
Provider Variability in the Use of Neuromuscular Blocking Drugs and Reversal
NCT03585348 ·Status: COMPLETED